Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-475 plus simvastatin in primary dyslipidemia
2005-002313-21Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lapaquistat in primary dyslipidaemia (3 arms), sponsored by Takeda. Primary endpoint: Change in fasting plasma LDL-cholesterol. Started Jul 2005; status: completed.
02
Drugs
lapaquistat
03
Conditions
primary dyslipidaemia
Beyond the preview
Go deeper on 2005-002313-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002313-21.